About Interferon-inducible double-stranded RNA-dependent protein kinase activator A
Interferon-inducible double-stranded RNA-dependent protein kinase activator A (PRKRA) is a protein
from Homo sapiens identified by UniProt accession
O75569, 313 residues long.
MolForge cross-references it against 0 known binders and
118 disease associations.
Target properties
| Protein name | Interferon-inducible double-stranded RNA-dependent protein kinase activator A |
| UniProt accession | O75569 |
| Gene | PRKRA |
| Organism | Homo sapiens |
| Length | 313 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (118)
Diseases linked to this target (Open Targets).
- dystonia 16 · score 0.75
- Dystonia · score 0.51
- blood protein measurement · score 0.33
- Epstein Barr virus nuclear antigen 1 IgG measurement · score 0.21
- muscular disease · score 0.21
- genetic disorder · score 0.17
- dystonic disorder · score 0.16
- electrocardiography · score 0.12
- forced expiratory volume · score 0.12
- age at onset · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75569-F1 | alphafold | PREDICTED | 75.43 | — |
Amino-acid sequence (313 residues)
MSQSRHRAEA PPLEREDSGT FSLGKMITAK PGKTPIQVLH EYGMKTKNIP VYECERSDVQ IHVPTFTFRV TVGDITCTGE GTSKKLAKHR AAEAAINILK ANASICFAVP DPLMPDPSKQ PKNQLNPIGS LQELAIHHGW RLPEYTLSQE GGPAHKREYT TICRLESFME TGKGASKKQA KRNAAEKFLA KFSNISPENH ISLTNVVGHS LGCTWHSLRN SPGEKINLLK RSLLSIPNTD YIQLLSEIAK EQGFNITYLD IDELSANGQY QCLAELSTSP ITVCHGSGIS CGNAQSDAAH NALQYLKIIA ERK
Explore Interferon-inducible double-stranded RNA-dependent protein kinase activator A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets